311 results
10-K405
2001 FY
EX-10.6.6
TOVX
Theriva Biologics Inc
29 Mar 02
Annual report (delinquent filer disclosure)
12:00am
of his right to
receive benefits until the Termination Date during the pendency of any dispute
or controversy arising under or in connection …
2
the Executive with the payments and benefits set forth in Paragraph 29 below
(collectively, the "Enhanced Severance
10-K405
2001 FY
EX-10.6
TOVX
Theriva Biologics Inc
29 Mar 02
Annual report (delinquent filer disclosure)
12:00am
of his right to
receive benefits until the Termination Date during the pendency of any dispute
or controversy arising under or in connection …
the Executive with the payments and benefits set forth in Paragraph 28 below
(collectively, the "Enhanced
2
10-K405
2001 FY
EX-10.6.5
TOVX
Theriva Biologics Inc
29 Mar 02
Annual report (delinquent filer disclosure)
12:00am
performance of his right to
receive benefits until the Termination Date during the pendency of any dispute
or controversy arising under or in connection …
2
the Executive with the payments and benefits set forth in Paragraph 29 below
(collectively, the "Enhanced
10-K405
2001 FY
EX-10.13
TOVX
Theriva Biologics Inc
29 Mar 02
Annual report (delinquent filer disclosure)
12:00am
of his right to
receive benefits until the Termination Date during the pendency of any dispute
or controversy arising under or in connection …
2
the Executive with the payments and benefits set forth in Paragraph 29 below
(collectively, the "Enhanced Severance
8-K
EX-10.1
TOVX
Theriva Biologics Inc
6 Dec 18
Termination of a Material Definitive Agreement
4:59pm
and the Executive’s rights with respect to the grants thereunder shall continue.
7. EMPLOYEE BENEFITS.
(a) BENEFIT PLANS. The Executive shall, in accordance … senior management. All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions
8-K
EX-10.1
wk4zhv67gzle eg43
4 Jan 22
Departure of Directors or Certain Officers
5:21pm
8-K
EX-10.1
qh9trv1bwpx5
23 Mar 22
Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation
8:30am
10-K
EX-10.20
3p6izi
15 Apr 98
Annual report
12:00am
8-K
EX-99.1
dqxlckbz 4xvii
27 Jun 23
Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer
5:11pm
8-K
EX-99.1
lqo8bd2pq8
7 Jan 20
Other Events
7:05am
8-K
u6yg586j9hukerkailvp
6 Feb 12
Adeona Announces Executive Management Transitions and Board of Directors Appointments
12:00am
S-8
EX-4.13
tplteoc9w0cc12y8d31d
28 Oct 20
Registration of securities for employees
5:23pm
8-K
mlss44a66lptsg8l5twk
7 Feb 12
Adeona Appoints C. Evan Ballantyne as Chief Financial Officer
12:00am
8-K
oe56um82ky54jlo5uyd
6 Dec 18
Termination of a Material Definitive Agreement
4:59pm
S-8
EX-4.12
63l 78e8e0
28 Oct 20
Registration of securities for employees
5:23pm
8-K
gejsx1unarq4w75g6h
23 Mar 22
Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation
8:30am
S-8
EX-4.11
ds9ymqrt58s7c uw
28 Oct 20
Registration of securities for employees
5:23pm